Literature DB >> 6321667

Cell lines (VMDk) derived from a spontaneous murine astrocytoma. Morphological and immunocytochemical characterization.

G J Pilkington, J L Darling, P L Lantos, D G Thomas.   

Abstract

Three cell lines (VMDk) derived from a spontaneous, murine astrocytoma, which produce tumours when injected either subcutaneously or intracranially into syngeneic mice, have been examined in vitro. Ultrastructurally, the cells show astrocytic features but each line differs in its degree of differentiation. Treatment with both dexamethasone and dibutyryl adenosine 3',5'-cyclic monophosphate (dbcAMP) increases intracytoplasmic differentiation and causes surface structural changes. The addition of dbcAMP also induces a statistically significant increase in the length and number of cell processes. All three cell lines express the astrocyte-specific markers, glial fibrillary acidic protein (GFAP) and glutamine synthetase (GS), by indirect immunofluorescence, with two lines showing an increased propensity to stain for GFAP following dbcAMP treatment. The cell surface antigen fibronectin is also detected in all lines. Thus these VMDK cell lines exhibit both the morphological and antigenic characteristics of astrocytes and respond to dexamethasone and dbcAMP and may be used to provide a suitable in vivo-in vitro model system for the study of astrocytoma.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6321667     DOI: 10.1016/0022-510x(83)90193-4

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  10 in total

1.  The VM model of glioma: preparation of multicellular tumour spheroids (MTS) and their response to chemotherapy.

Authors:  R Bradford; J L Darling; N Sier; D G Thomas
Journal:  J Neurooncol       Date:  1990-10       Impact factor: 4.130

2.  The in-vitro chemosensitivity of three cell lines derived from the VM/DK spontaneous murine astrocytoma.

Authors:  R Bradford; J L Darling; D G Thomas
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-12       Impact factor: 10.154

3.  Local interstitial chemotherapy with sustained release bucladesine in de novo glioblastoma multiforme: a preliminary study.

Authors:  Tayfun Dalbasti; Nezih Oktar; Sedat Cagli; Nurcan Ozdamar
Journal:  J Neurooncol       Date:  2002-01       Impact factor: 4.130

4.  Cloned neoplastic cells from a chemically-induced rat glioma: immunocytochemical characterization.

Authors:  G J Pilkington; J M Martin; P L Lantos
Journal:  Br J Exp Pathol       Date:  1985-10

Review 5.  Immunocompetent murine models for the study of glioblastoma immunotherapy.

Authors:  Taemin Oh; Shayan Fakurnejad; Eli T Sayegh; Aaron J Clark; Michael E Ivan; Matthew Z Sun; Michael Safaee; Orin Bloch; Charles D James; Andrew T Parsa
Journal:  J Transl Med       Date:  2014-04-29       Impact factor: 5.531

6.  Mistletoe-Based Drugs Work in Synergy with Radio-Chemotherapy in the Treatment of Glioma In Vitro and In Vivo in Glioblastoma Bearing Mice.

Authors:  Sonja Schötterl; Jennifer T Miemietz; Elena I Ilina; Naita M Wirsik; Ingrid Ehrlich; Andrea Gall; Stephan M Huber; Hans Lentzen; Michel Mittelbronn; Ulrike Naumann
Journal:  Evid Based Complement Alternat Med       Date:  2019-07-03       Impact factor: 2.629

Review 7.  Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies.

Authors:  Maria B Garcia-Fabiani; Santiago Haase; Andrea Comba; Stephen Carney; Brandon McClellan; Kaushik Banerjee; Mahmoud S Alghamri; Faisal Syed; Padma Kadiyala; Felipe J Nunez; Marianela Candolfi; Antonela Asad; Nazareno Gonzalez; Marisa E Aikins; Anna Schwendeman; James J Moon; Pedro R Lowenstein; Maria G Castro
Journal:  Front Oncol       Date:  2021-06-08       Impact factor: 5.738

8.  Fermented mistletoe extract as a multimodal antitumoral agent in gliomas.

Authors:  Oliver Podlech; Patrick N Harter; Michel Mittelbronn; Simone Pöschel; Ulrike Naumann
Journal:  Evid Based Complement Alternat Med       Date:  2012-10-22       Impact factor: 2.629

9.  The chemotherapeutic response of a murine (VM) model of human glioma.

Authors:  R Bradford; J L Darling; D G Thomas
Journal:  Br J Cancer       Date:  1990-01       Impact factor: 7.640

10.  Adjuvant Therapy Using Mistletoe Containing Drugs Boosts the T-Cell-Mediated Killing of Glioma Cells and Prolongs the Survival of Glioma Bearing Mice.

Authors:  Sonja Schötterl; Stephan M Huber; Hans Lentzen; Michel Mittelbronn; Ulrike Naumann
Journal:  Evid Based Complement Alternat Med       Date:  2018-08-27       Impact factor: 2.629

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.